文献速递骨显像与常规 SPECT放射性药物与辐射防护

术前骨SPECT/CT定量标准化摄取值预测药物相关性颌骨坏死术后愈合反应的价值

Utility of quantitative standardized uptake value from pre-operative bone SPECT/CT for predicting post-surgical MRONJ healing response.
PubMed 文献 · EJNMMI Res · 2025-03-31

本研究纳入57例接受手术治疗的药物相关性颌骨坏死(MRONJ)患者,分析术前骨SPECT/CT的最大标准化摄取值(SUVmax)及病灶SUVmax与参考区平均SUV比值(rSUVmax)与手术结局的关系。多因素logistic回归显示,较高的rSUVmax与较差手术结局显著相关(OR 1.51,95%CI 1.07-2.14),而SUVmax无显著关联(OR 1.05,95%CI 0.98-1.13)。作者认为rSUVmax可能作为评估MRONJ严重程度和预测手术结局的预后工具。

要点

  • rSUVmax较高与MRONJ术后未愈合显著相关(OR 1.51,95%CI 1.07-2.14)。
  • SUVmax与手术结局无显著关联(OR 1.05,95%CI 0.98-1.13)。
  • 术前MRONJ分期未能显著预测MRONJ愈合。

核心结论

  • 骨SPECT/CT的rSUVmax可能作为评估MRONJ严重程度和预测手术结局的预后工具。
  • 将rSUVmax测量纳入临床实践可能增强决策并改善患者管理。

研究设计与样本

  • 分析了57例接受手术治疗的MRONJ患者队列,术前骨SPECT/CT获取病灶SUVmax及rSUVmax,采用logistic回归分析并调整年龄、性别、糖尿病、骨改良药物类型、MRONJ受累部位和分期等混杂因素。

主要发现

  • SUVmax和rSUVmax值均随MRONJ分期从1期进展至3期而升高,且未愈合组高于完全愈合组。
  • 多因素logistic回归显示较高的rSUVmax与较差手术结局显著相关(OR 1.51,95%CI 1.07-2.14)。
  • SUVmax与手术结局无显著关联(OR 1.05,95%CI 0.98-1.13)。
  • 术前MRONJ分期未能显著预测MRONJ愈合。

关键数值与推荐

  • rSUVmax每升高1单位,手术结局不良的OR为1.51(95%CI 1.07-2.14)。
  • SUVmax的OR为1.05(95%CI 0.98-1.13),无显著关联。

临床怎么用

  • 作者认为rSUVmax可能作为评估MRONJ严重程度和预测手术结局的预后工具,将rSUVmax测量纳入临床实践可能增强决策并改善患者管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition often associated with long-term use of anti-resorptive medications. Accurate diagnosis is essential, but predicting the prognosis is particularly difficult due to the high likelihood of recurrence after surgery. This study assesses the utility of quantitative values from bone SPECT/CT as predictors of surgical outcomes in MRONJ patients. MATERIALS AND METHODS: We analyzed a cohort of 57 MRONJ patients who underwent surgical treatment. Preoperative bone SPECT/CT scans were used to obtain the maximal SUV (SUVmax) of MRONJ lesions and the ratio of the SUVmax to the mean SUV of a reference region (rSUVmax). Logistic regression analysis was performed to evaluate the relationship between preoperative SUVmax and rSUVmax and surgical outcomes, adjusting for confounders such as age, sex, diabetes, type of bone-modifying agent, MRONJ-affected sites, and stage. RESULTS: Both SUVmax and rSUVmax values increased with the progression from MRONJ stage 1 to stage 3 and were higher in the No Resolution group compared to the Complete Resolution group. Multivariate logistic regression analysis revealed that higher rSUVmax values were significantly associated with poor surgical outcomes (OR, 1.51; 95% CI, 1.07-2.14), whereas SUVmax values were not significantly associated (OR, 1.05; 95% CI, 0.98-1.13). Preoperative MRONJ stages did not significantly predict MRONJ resolution. CONCLUSION: rSUVmax from bone SPECT/CT may serve as a valuable prognostic tool for assessing MRONJ severity and predicting surgical outcomes. Incorporating rSUVmax measurements into clinical practice could enhance decision-making and improve patient management. CLINICAL TRIAL REGISTRATION: None.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Park JH, Yoon DM, Yoon HJ, et al. Utility of quantitative standardized uptake value from pre-operative bone SPECT/CT for predicting post-surgical MRONJ healing response. EJNMMI Res. 2025. PMID: 40164939. doi:10.1186/s13550-025-01220-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。